[Oral terbinafine-induced plantar pustular psoriasis].
BACKGROUND
Cutaneous reactions may occur in patients receiving terbinafine therapy, mainly rash and urticaria. More exceptionally, development of psoriasis has been described. We describe the development of plantar pustular psoriasis in a patient who took oral terbinafine.


METHODS
A 70-year-old man, without previously known history of psoriasis, was treated with terbinafine, 250 mg/day, for onychomycosis. Ten days later, a plantar pustular psoriasis appeared. The psoriasis cleared up after discontinuation of terbinafine and institution of antipsoriatic therapy.


CONCLUSIONS
Terbinafine is an antifungal agent widely use in the treatment of onychomycosis. A skin reaction occurs in 3 p. 100 of patients. Only 24 cases of flare-up of previous psoriasis or psoriasis de novo after terbinafine have been described. The psoriasis generally clears after discontinuation of terbinafine. So, terbinafine is perhaps not the best first line therapy for onychomycosis in patients with psoriasis.
Le Guyadec
T
T
Service de Dermatologie, Hôpital d'Instruction des Armées Percy, 101, avenue Henri-Barbusse, 92141 Clamart Cedex.
Saint-Blancard
P
P
Bosonnet
S
S
Le Vagueresse
R
R
Lanternier
G
G
D000284:Administration, Oral; D000368:Aged; D000935:Antifungal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001706:Biopsy; D003875:Drug Eruptions / Q000175:diagnosis* / Q000473:pathology; D005533:Foot Dermatoses / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology; D006801:Humans; D008297:Male; D009281:Naphthalenes / Q000009:adverse effects* / Q000627:therapeutic use; D014009:Onychomycosis / Q000188:drug therapy; D011565:Psoriasis / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology; D012867:Skin / Q000473:pathology; D000077291:Terbinafine
D000935:Antifungal Agents; D009281:Naphthalenes; D000077291:Terbinafine